Kailera Therapeutics (NASDAQ:KLRA) Coverage Initiated at Evercore

Investment analysts at Evercore began coverage on shares of Kailera Therapeutics (NASDAQ:KLRA) in a report released on Tuesday. The firm set an “outperform” rating on the stock.

Several other equities research analysts also recently weighed in on the company. Wall Street Zen raised Kailera Therapeutics to a “hold” rating in a report on Saturday, April 25th. William Blair started coverage on Kailera Therapeutics in a research report on Tuesday. They set an “outperform” rating for the company. TD Cowen started coverage on Kailera Therapeutics in a research report on Tuesday. They set a “buy” rating and a $57.00 target price for the company. Finally, Jefferies Financial Group started coverage on Kailera Therapeutics in a research report on Tuesday. They set a “buy” rating and a $48.00 target price for the company. Six analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $42.75.

Kailera Therapeutics Trading Up 6.8%

NASDAQ KLRA opened at $22.93 on Tuesday. Kailera Therapeutics has a twelve month low of $20.86 and a twelve month high of $28.23.

Insider Buying and Selling

In related news, Director Andrew T. Kaplan bought 8,398,438 shares of the stock in a transaction that occurred on Monday, April 20th. The stock was acquired at an average cost of $16.00 per share, with a total value of $134,375,008.00. Following the transaction, the director directly owned 26,255,581 shares in the company, valued at approximately $420,089,296. This trade represents a 47.03% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Adam Koppel acquired 1,562,500 shares of the stock in a transaction dated Monday, April 20th. The stock was acquired at an average cost of $16.00 per share, with a total value of $25,000,000.00. Following the completion of the transaction, the director owned 22,583,268 shares in the company, valued at approximately $361,332,288. This represents a 7.43% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased a total of 10,460,938 shares of company stock valued at $167,375,008 in the last three months.

Kailera Therapeutics Company Profile

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.